Mi SciELO
Servicios Personalizados
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista Cubana de Farmacia
versión On-line ISSN 1561-2988
Resumen
TARINAS REYES, Alicia et al. Bioequivalence study: generic and trade formulations of stavudine, lamivudine, zidovudine and indinavir in Cuban HIV-infected subjects. Rev Cubana Farm [online]. 2006, vol.40, n.2, pp. 0-0. ISSN 1561-2988.
Objective: The present study describes the determination of the bioequivalence of the Cuban generic and trade formulations of stavudine, lamivudine, zidovudine, and indinavir. Design: The bioequivalence of each antiretroviral drug (test and reference formulations) was determined in 13 or 14subjects by means of a randomizedcrossover blind study with a wash-outperiod of ten days. Methods: The plasma concentrations were monitored over a period of 12 h after drug administration using a validated HPLC method. The pharmacokinetic parameters were determined by using WinNolin Professional software, Version 2.1. The comparison of the pharmacokinetic parameters was made at 95 % confidence interval using the NCSS 2000 and PASS 2000 trial software (paired t-test, null hypothesis).The bioequivalence study was conducted by the EqivTest software of statistical solutions. ANOVA was utilized with 90 % confidence interval. Results: The present study showed that no significant differences were observed in the means of AUC0-12, AUC0-¥, C max, and T max of both formulations of stavudine, lamivudine zidovudine, and indinavir. It wasconcluded that the studied pharmacokinetic parameters are withinthe established range. The ranges for Cmax, AUC0-12, and AUC0-¥ were 80-125 %, whereasthe range for Cmax of zidovudine was 70-143 %. Conclusion: These results prove that the Cuban generic antiretroviralsare bioequivalent to their respective innovatory products in terms ofthe rate and extent of absorption
Palabras clave : Antiretroviral; bioequivalence; HPLC; HIV; generic drugs.